Zacks Investment Research downgraded shares of SMITH & NEPHEW (SNN) from OUTPERFORM to NEUTRAL on March 06, 2013, with a target price of $59.10.
Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physician advantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment to deliver new levels of healing to patients throughout the world
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on SMITH & NEPHEW (SNN),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment